版本:
中国

BRIEF-Sumitomo Dainippon Pharma looks to expand applications of drug candidate Dasotraline - Nikkei

March 24 Nikkei

* Sumitomo Dainippon Pharma Co Ltd looks to expand the applications of its drug candidate dasotraline - Nikkei

* Sumitomo Dainippon Pharma's candidate dasotraline has been tested in trials as ADHD treatment,now being studied as treatment for eating disorder -Nikkei

* Sumitomo Dainippon Pharma Co Ltd aims to begin sales of dasotraline in fiscal 2018 - Nikkei

* Sumitomo dainippon pharma co expects to file NDA with U.S. FDA in fiscal 2017 for ADHD indication and following year for binge eating disorder - Nikkei Source text : [s.nikkei.com/2n0i6kY] Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐